12:00 AM
Dec 17, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

EBI-005: Phase Ib started

Eleven began a double-blind, placebo-controlled, U.S. Phase Ib trial to evaluate 5 and 20 mg/mL EBI-005 ophthalmic solution 3 times per day for 6...

Read the full 96 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >